Gene Biotherapeutics, Inc.

CRXM · OTC
Analyze with AI
12/31/2020
9/30/2020
6/30/2020
3/31/2020
Operating Activities
Net Income-$490-$401$408-$169
Dep. & Amort.$1$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC$220-$152$37$75
Other Non-Cash-$69$73-$667$0
Operating Cash Flow-$338-$480-$221-$94
Investing Activities
PP&E Inv.-$0-$3$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$0-$3$0$0
Financing Activities
Debt Repay.-$192$12$72$96
Stock Issued$600$0$0$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$135-$60$1,459$0
Financing Cash Flow-$58-$48$1,531$96
Forex Effect$0$0$0$0
Net Chg. in Cash-$396-$531$1,310$3
Supplemental Information
Beg. Cash$782$1,312$3$0
End Cash$386$782$1,312$3
Free Cash Flow-$338-$483-$221-$94
Gene Biotherapeutics, Inc. (CRXM) Financial Statements & Key Stats | AlphaPilot